{"id":11624,"date":"2018-04-13T13:10:03","date_gmt":"2018-04-13T11:10:03","guid":{"rendered":"https:\/\/www.bm-t.de\/v4\/2021\/fight-against-tuberculosis-hapila-is-involved\/"},"modified":"2021-02-03T10:37:00","modified_gmt":"2021-02-03T09:37:00","slug":"fight-against-tuberculosis-hapila-is-involved","status":"publish","type":"post","link":"https:\/\/www.bm-t.de\/en\/2018-en\/fight-against-tuberculosis-hapila-is-involved\/","title":{"rendered":"Fight against tuberculosis \u2014 HAPILA is involved"},"content":{"rendered":"<p>World\u00adwide, tuber\u00adcu\u00adlo\u00adsis claims about 1.5 mil\u00adlion vic\u00adtims per year. It is one of the most dan\u00adger\u00adous dis\u00adeases caused by bac\u00adte\u00adria. The increas\u00ading spread of multi-resis\u00adtant strains of the pathogen is par\u00adtic\u00adu\u00adlarly wor\u00adry\u00ading. A group of researchers and entre\u00adpre\u00adneurs is cur\u00adrently devel\u00adop\u00ading an antibi\u00adotic with pub\u00adlic fund\u00ading that is also effec\u00adtive against resis\u00adtant strains.<br>\nA promis\u00ading active sub\u00adstance against tuber\u00adcu\u00adlo\u00adsis is now about to undergo clin\u00adi\u00adcal tri\u00adals. The active ingre\u00addi\u00adent is being man\u00adu\u00adfac\u00adtured by HAPILA GmbH, a port\u00adfo\u00adlio com\u00adpany of bm|t.<br>\n<a href=\"https:\/\/youtu.be\/Za3ZuUz_dmY\">https:\/\/youtu.be\/<\/a><\/p>\n<p><a href=\"https:\/\/www.infectcontrol.de\/de\/anzeigen\/aussichtsreicher-wirkstoff-gegen-tuberkulose-steht-vor-klinischer-erprobung.html\">www.infectcontrol.de\/de\/anzeigen\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>World\u00adwide, tuber\u00adcu\u00adlo\u00adsis claims about 1.5 mil\u00adlion vic\u00adtims per year. It is one of the most dan\u00adger\u00adous dis\u00adeases caused by bac\u00adte\u00adria. The increas\u00ading spread of multi-resis\u00ad\u00adtant strains of the pathogen is par\u00adtic\u00adu\u00adlarly wor\u00adry\u00ading. A group of researchers and entre\u00adpre\u00adneurs is cur\u00adrently devel\u00adop\u00ading an antibi\u00adotic with pub\u00adlic fund\u00ading that is also effec\u00adtive against resis\u00adtant strains. A promising&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[147],"tags":[],"class_list":["post-11624","post","type-post","status-publish","format-standard","hentry","category-2018-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11624","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/comments?post=11624"}],"version-history":[{"count":0,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/posts\/11624\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/media?parent=11624"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/categories?post=11624"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bm-t.de\/en\/wp-json\/wp\/v2\/tags?post=11624"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}